DMRA Stock Summary and Trading Ideas (Damora Therapeutics | NASDAQ:DMRA)

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

What symbol and exchange does Damora Therapeutics shares trade?

Damora Therapeutics trades on the NASDAQ stock market under the symbol DMRA.

What is Damora Therapeutics stock price doing today?

As of April 22, 2026, DMRA stock price declined to $25.90 with 145,376 million shares trading.

How much is Damora Therapeutics worth?

DMRA has a market cap of $1.56 billion. This is considered a Small Cap stock.

What are the top ETFs holding Damora Therapeutics?

The top ETF exchange traded funds that DMRA belongs to (by Net Assets): VXF, XBI, ONEQ, LABU.

What are the support and resistance levels for Damora Therapeutics (DMRA)?

DMRA support price is $25.17 and resistance is $28.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMRA shares will trade within this expected range on the day.